ARS Pharmaceuticals Inc (NAS:SPRY)
$ 8.88 -0.1 (-1.11%) Market Cap: 860.43 Mil Enterprise Value: 646.70 Mil PE Ratio: 0 PB Ratio: 3.87 GF Score: 19/100

ARS Pharmaceuticals Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript

Feb 16, 2023 / 07:20PM GMT
Release Date Price: $8.29 (-0.18%)
Roanna Ruiz
SVB Securities LLC - Analyst

Great. Welcome back everyone to our next session. I'm Roanna Ruiz, Senior Biotech Analyst here at SVB Securities, and it's my pleasure to introduce the management team of ARS Pharmaceuticals.

First we have Richard Lowenthal, CEO; and Eric Karas, Chief Commercial Officer. So thanks both for joining us. And we're going to kick it off a little bit with some bigger picture questions. So maybe, could you just give us a brief overview of the company and your lead intranasal epinephrine product, neffy?

Richard Lowenthal
ARS Pharmaceuticals, Inc. - President & CEO

Yes. Thank you, Roanna. So we started ARS a number of years ago, really, with the explicit focus of developing needle-free nasal spray with epinephrine that can achieve injection-like levels, therapeutic levels of epinephrine to solve a lot of problems in the community.

And at the time, we are working on a number of other nasal spray products that we're proud to have been involved in and are on the market. And we're also working with the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot